Why the study?
Metabolic heart failure treatments aiming to stimulate glucose oxidation or inhibit fatty acid oxidation have failed to provide meaningful clinical benefits, prompting a rethink of the concept that fat is harmful to the failing heart.
Design
Review
Key result
Short-chain fatty acids may serve as an effective alternative fuel and anti-inflammatory treatment for the failing heart, bypassing the downregulated long-chain fatty acid transporters.
Authors
Loading...
Metabolic modulation in HF should not yet change practice; leaves open whether substrate shifts improve outcomes.
This review highlights the potential of short-chain fatty acids as a novel metabolic and anti-inflammatory therapy for heart failure, challenging the traditional view that all fats are detrimental to the failing heart.
Palm et al. (2022) conducted a review in Heart failure. Short-chain fatty acids (SCFAs) was evaluated. Short-chain fatty acids may serve as an effective alternative fuel and anti-inflammatory treatment for the failing heart, bypassing the downregulated long-chain fatty acid transporters.